|
Aug 6
|
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share
|
|
Aug 5
|
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 5
|
Madrigal: Q2 Earnings Snapshot
|
|
Aug 5
|
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
|
|
Jul 30
|
Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval
|
|
Jul 30
|
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
|
|
Jul 26
|
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
|
|
Jul 25
|
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
|
|
Jul 25
|
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion
|
|
Jul 22
|
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
|
|
Jul 17
|
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
|
|
Jul 17
|
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
|
|
Jul 16
|
Sector Update: Health Care Stocks Climb Late Afternoon
|
|
Jul 16
|
Sector Update: Health Care Stocks Gain in Afternoon Trading
|
|
Jul 16
|
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
|
|
Jul 2
|
JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential
|
|
Jun 24
|
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
|
|
Jun 20
|
Madrigal poised to enter European MASH market after CHMP endorsement
|
|
Jun 20
|
Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount
|
|
Jun 20
|
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
|